Head and neck squamous cell carcinoma (HNSCC) is a complex cancer requiring a multidisciplinary approach. For patients with locally or regionally advanced disease, surgery and/or radiation are the cornerstones of definitive treatment. Medical therapy plays an important adjunct role in this setting, typically consisting of a platinum-based regimen given as induction, concurrent, or adjuvant treatment. While relapsed/metastatic HNSCC has historically been a difficult-to-treat disease with poor outcomes, options have considerably improved with the incorporation of biologics and immune checkpoint inhibitors. Clinical trials are ongoing to investigate novel approaches, including new and combination immunotherapies, targeted therapies, therapeutic vaccines, antibody–drug conjugates, and cellular therapies. The results thus far have been mixed, highlighting the knowledge gaps that continue to challenge the medical oncologist treating HNSCC. Here, we present the most updated and broad review of the current treatment landscape in both locoregional and metastatic HNSCC and discuss the expansive future medical therapies under investigation.
头颈部鳞状细胞癌（HNSCC）是一种复杂的恶性肿瘤，需要多学科综合治疗。对于局部或区域晚期患者，手术和/或放疗是根治性治疗的基石。药物治疗在此背景下发挥着重要的辅助作用，通常采用以铂类药物为基础的方案，作为诱导、同步或辅助治疗。尽管复发/转移性头颈部鳞状细胞癌历来是一种治疗困难且预后较差的疾病，但随着生物制剂和免疫检查点抑制剂的引入，治疗选择已显著改善。目前正在进行多项临床试验，以探索新型治疗方法，包括新型及联合免疫疗法、靶向治疗、治疗性疫苗、抗体-药物偶联物以及细胞疗法。迄今为止，这些研究结果参差不齐，凸显了在治疗头颈部鳞状细胞癌过程中，肿瘤内科医生仍面临诸多知识空白。本文旨在对当前局部区域性和转移性头颈部鳞状细胞癌的治疗现状进行最新、全面的综述，并探讨正在研究中的广阔未来药物治疗前景。
Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma
肿瘤(癌症)患者之家